{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:24:46Z","timestamp":1794021886247,"version":"4.8.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41577-021-00549-4","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T06:04:53Z","timestamp":1621231493000},"page":"19-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":484,"title":["Immunobiology and pathogenesis of hepatitis B virus infection"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-2671","authenticated-orcid":false,"given":"Matteo","family":"Iannacone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-2678","authenticated-orcid":false,"given":"Luca G.","family":"Guidotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","volume":"1","author":"LG Guidotti","year":"2006","unstructured":"Guidotti, L. G. & Chisari, F. V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. Mech. Dis. 1, 23\u201361 (2006).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","volume":"62","author":"S Locarnini","year":"2015","unstructured":"Locarnini, S., Hatzakis, A., Chen, D.-S. & Lok, A. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J. Hepatol. 62, S76\u2013S86 (2015).","journal-title":"J. Hepatol."},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"M-F Yuen","year":"2018","unstructured":"Yuen, M.-F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545\u2013558 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cld.904","volume":"15","author":"P Udompap","year":"2020","unstructured":"Udompap, P. & Kim, W. R. Development of hepatocellular carcinoma in patients with suppressed viral replication: changes in risk over time. Clin. Liver Dis. 15, 85\u201390 (2020).","journal-title":"Clin. Liver Dis."},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.coviro.2016.06.003","volume":"18","author":"M Levrero","year":"2016","unstructured":"Levrero, M., Testoni, B. & Zoulim, F. HBV cure: why, how, when? Curr. Opin. Virol. 18, 135\u2013143 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"549_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov. 18, 827\u2013844 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104\u20131108 (1996).","journal-title":"Nat. Med."},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1172\/JCI107284","volume":"52","author":"CY Kim","year":"1973","unstructured":"Kim, C. Y. & Tilles, J. G. Purification and biophysical characterization of hepatitis B antigen. J. Clin. Invest. 52, 1176\u20131186 (1973).","journal-title":"J. Clin. Invest."},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479","author":"C Seeger","year":"2015","unstructured":"Seeger, C. & Mason, W. S. Molecular biology of hepatitis B virus infection. Virology 479, 672\u2013686 (2015).","journal-title":"Virology"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","volume":"64","author":"A Bertoletti","year":"2016","unstructured":"Bertoletti, A. & Ferrari, C. Adaptive immunity in HBV infection. J. Hepatol. 64, S71\u2013S83 (2016).","journal-title":"J. Hepatol."},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","volume":"36","author":"LG Guidotti","year":"2015","unstructured":"Guidotti, L. G., Isogawa, M. & Chisari, F. V. Host\u2013virus interactions in hepatitis B virus infection. Curr. Opin. Immunol. 36, 61\u201366 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"e02007","DOI":"10.1128\/JVI.02007-17","volume":"92","author":"T Tu","year":"2018","unstructured":"Tu, T. et al. Integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J. Virol. 92, e02007\u2013e02017 (2018). This study shows that HBV DNA integration occurs\u00a0early upon infection in an in vitro infection\u00a0model.","journal-title":"J. Virol."},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"11652","DOI":"10.1073\/pnas.1635109100","volume":"100","author":"J Summers","year":"2003","unstructured":"Summers, J. et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc. Natl Acad. Sci. USA 100, 11652\u201311659 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.1128\/JVI.73.12.9710-9717.1999","volume":"73","author":"W Yang","year":"1999","unstructured":"Yang, W. & Summers, J. Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J. Virol. 73, 9710\u20139717 (1999).","journal-title":"J. Virol."},{"key":"549_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241","volume":"9","author":"CI Wooddell","year":"2017","unstructured":"Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl Med. 9, eaan0241 (2017). This paper reveals integrated HBV DNA as a relevant source of HBsAg in patients and chimpanzees with chronic infection.","journal-title":"Sci. Transl Med."},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018\u20131028 (2020). This manuscript represents one of a large number of meta-analyses describing an association between low-dose aspirin treatment and reduced HCC incidence.","journal-title":"N. Engl. J. Med."},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"E2165","DOI":"10.1073\/pnas.1209182109","volume":"109","author":"G Sitia","year":"2012","unstructured":"Sitia, G. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl Acad. Sci. USA 109, E2165\u2013E2172 (2012). This preclinical study shows that anti-platelet therapy reduces liver fibrosis and prevents HCC in mouse models of CHB.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1128\/CVI.00298-07","volume":"14","author":"M Iannacone","year":"2007","unstructured":"Iannacone, M., Sitia, G., Narvaiza, I., Ruggeri, Z. M. & Guidotti, L. G. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin. Vaccine Immunol. 14, 1532\u20131535 (2007).","journal-title":"Clin. Vaccine Immunol."},{"key":"549_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1006\/viro.1996.0661","volume":"226","author":"AR Jilbert","year":"1996","unstructured":"Jilbert, A. R., Miller, D. S., Scougall, C. A., Turnbull, H. & Burrell, C. J. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 226, 338\u2013345 (1996).","journal-title":"Virology"},{"key":"549_CR21","doi-asserted-by":"publisher","first-page":"9652","DOI":"10.1128\/JVI.00867-09","volume":"83","author":"S Asabe","year":"2009","unstructured":"Asabe, S. et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83, 9652\u20139662 (2009).","journal-title":"J. Virol."},{"key":"549_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/gt.2008.60","volume":"15","author":"E Wisse","year":"2008","unstructured":"Wisse, E., Jacobs, F., Topal, B., Frederik, P. & Geest, B. D. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193\u20131199 (2008).","journal-title":"Gene Ther."},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1152\/physrev.00027.2008","volume":"89","author":"B Vollmar","year":"2009","unstructured":"Vollmar, B. & Menger, M. D. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol. Rev. 89, 1269\u20131339 (2009).","journal-title":"Physiol. Rev."},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1084\/jem.193.7.847","volume":"193","author":"SA Whalley","year":"2001","unstructured":"Whalley, S. A. et al. Kinetics of acute hepatitis B virus infection in humans. J. Exp. Med. 193, 847\u2013854 (2001).","journal-title":"J. Exp. Med."},{"key":"549_CR25","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1128\/jvi.69.10.6158-6169.1995","volume":"69","author":"LG Guidotti","year":"1995","unstructured":"Guidotti, L. G., Matzke, B., Schaller, H. & Chisari, F. V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69, 6158\u20136169 (1995).","journal-title":"J. Virol."},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"284","author":"LG Guidotti","year":"1999","unstructured":"Guidotti, L. G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825\u2013829 (1999).","journal-title":"Science"},{"key":"549_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1073\/pnas.0308478100","volume":"101","author":"SF Wieland","year":"2004","unstructured":"Wieland, S. F., Spangenberg, H. C., Thimme, R., Purcell, R. H. & Chisari, F. V. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl Acad. Sci. USA 101, 2129\u20132134 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR28","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101, 6669\u20136674 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","volume":"154","author":"A Suslov","year":"2018","unstructured":"Suslov, A. et al. Virus does not interfere with innate immune responses in the human liver. Gastroenterology 154, 1778\u20131790 (2018).","journal-title":"Gastroenterology"},{"key":"549_CR30","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1073\/pnas.92.26.12398","volume":"92","author":"LV Tsui","year":"1995","unstructured":"Tsui, L. V., Guidotti, L. G., Ishikawa, T. & Chisari, F. V. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc. Natl Acad. Sci. USA 92, 12398\u201312402 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1128\/JVI.73.1.474-481.1999","volume":"73","author":"T Heise","year":"1999","unstructured":"Heise, T., Guidotti, L. G., Cavanaugh, V. J. & Chisari, F. V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. 73, 474\u2013481 (1999).","journal-title":"J. Virol."},{"key":"549_CR32","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1128\/JVI.73.7.5767-5776.1999","volume":"73","author":"T Heise","year":"1999","unstructured":"Heise, T., Guidotti, L. G. & Chisari, F. V. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J. Virol. 73, 5767\u20135776 (1999).","journal-title":"J. Virol."},{"key":"549_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1128\/JVI.74.5.2255-2264.2000","volume":"74","author":"H McClary","year":"2000","unstructured":"McClary, H., Koch, R., Chisari, F. V. & Guidotti, L. G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74, 2255\u20132264 (2000).","journal-title":"J. Virol."},{"key":"549_CR34","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","volume":"74","author":"SF Wieland","year":"2000","unstructured":"Wieland, S. F., Guidotti, L. G. & Chisari, F. V. Intrahepatic induction of \u03b1\/\u03b2 interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 74, 4165\u20134173 (2000).","journal-title":"J. Virol."},{"key":"549_CR35","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.4049\/jimmunol.169.9.5188","volume":"169","author":"K Kimura","year":"2002","unstructured":"Kimura, K., Kakimi, K., Wieland, S., Guidotti, L. G. & Chisari, F. V. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J. Immunol. 169, 5188\u20135195 (2002).","journal-title":"J. Immunol."},{"key":"549_CR36","doi-asserted-by":"publisher","first-page":"18187","DOI":"10.1073\/pnas.0708968104","volume":"104","author":"S Vilarinho","year":"2007","unstructured":"Vilarinho, S., Ogasawara, K., Nishimura, S., Lanier, L. L. & Baron, J. L. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc. Natl Acad. Sci. USA 104, 18187\u201318192 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR37","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","volume":"79","author":"M Isogawa","year":"2005","unstructured":"Isogawa, M., Robek, M. D., Furuichi, Y. & Chisari, F. V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79, 7269\u20137272 (2005).","journal-title":"J. Virol."},{"key":"549_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2018.01.008","volume":"30","author":"A Suslov","year":"2018","unstructured":"Suslov, A., Wieland, S. & Menne, S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr. Opin. Virol. 30, 9\u201317 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-micro-092611-150203","volume":"66","author":"A Iwasaki","year":"2012","unstructured":"Iwasaki, A. A virological view of innate immune recognition. Annu. Rev. Microbiol. 66, 177\u2013196 (2012).","journal-title":"Annu. Rev. Microbiol."},{"key":"549_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1053\/jhep.2000.19324","volume":"32","author":"GJM Webster","year":"2000","unstructured":"Webster, G. J. M. et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117\u20131124 (2000).","journal-title":"Hepatology"},{"key":"549_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68\u201376 (2003).","journal-title":"J. Virol."},{"key":"549_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(73)92004-7","volume":"302","author":"JH Hoofnagle","year":"1973","unstructured":"Hoofnagle, J. H., Gerety, R. J. & Barker, L. F. Antibody to hepatitis-B-virus core in man. Lancet 302, 869\u2013873 (1973).","journal-title":"Lancet"},{"key":"549_CR43","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","volume":"16","author":"MK Maini","year":"2019","unstructured":"Maini, M. K. & Burton, A. R. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat. Rev. Gastroenterol. Hepatol. 16, 662\u2013675 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"549_CR44","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","volume":"91","author":"LG Guidotti","year":"1994","unstructured":"Guidotti, L. G. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA 91, 3764\u20133768 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","volume":"4","author":"LG Guidotti","year":"1996","unstructured":"Guidotti, L. G. et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25\u201336 (1996).","journal-title":"Immunity"},{"key":"549_CR46","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jhep.2015.05.033","volume":"63","author":"YC Wong","year":"2015","unstructured":"Wong, Y. C., Tay, S. S., McCaughan, G. W., Bowen, D. G. & Bertolino, P. Immune outcomes in the liver: is CD8 T cell fate determined by the environment? J. Hepatol. 63, 1005\u20131014 (2015).","journal-title":"J. Hepatol."},{"key":"549_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003490","volume":"9","author":"Isogawa","year":"2013","unstructured":"Isogawa et al. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog. 9, e1003490 (2013).","journal-title":"PLoS Pathog."},{"key":"549_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","volume":"574","author":"AP B\u00e9n\u00e9chet","year":"2019","unstructured":"B\u00e9n\u00e9chet, A. P. et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574, 200\u2013205 (2019). This paper reveals that hepatocellular priming leads to a T cell dysfunction that is refractory to checkpoint inhibition but responds to IL-2.","journal-title":"Nature"},{"key":"549_CR49","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/intimm\/11.8.1225","volume":"11","author":"P Bertolino","year":"1999","unstructured":"Bertolino, P. et al. Death by neglect as a deletional mechanism of peripheral tolerance. Int. Immunol. 11, 1225\u20131238 (1999).","journal-title":"Int. Immunol."},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1084\/jem.20191247","volume":"217","author":"Pol","year":"2020","unstructured":"Pol et al. Effects of interleukin-2 in immunostimulation and immunosuppression. J. Exp. Med. 217, 2261 (2020).","journal-title":"J. Exp. Med."},{"key":"549_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm866","volume":"9","author":"JN Blattman","year":"2003","unstructured":"Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540\u2013547 (2003).","journal-title":"Nat. Med."},{"key":"549_CR52","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1172\/JCI67008","volume":"123","author":"EE West","year":"2013","unstructured":"West, E. E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604\u20132615 (2013).","journal-title":"J. Clin. Invest."},{"key":"549_CR53","doi-asserted-by":"publisher","first-page":"104816","DOI":"10.1016\/j.antiviral.2020.104816","volume":"179","author":"A Kuipery","year":"2020","unstructured":"Kuipery, A., Gehring, A. J. & Isogawa, M. Mechanisms of HBV immune evasion. Antivir. Res. 179, 104816 (2020).","journal-title":"Antivir. Res."},{"key":"549_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","volume":"143","author":"PTF Kennedy","year":"2012","unstructured":"Kennedy, P. T. F. et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143, 637\u2013645 (2012).","journal-title":"Gastroenterology"},{"key":"549_CR55","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.4049\/jimmunol.161.9.4520","volume":"161","author":"Y Shimizu","year":"1998","unstructured":"Shimizu, Y., Guidotti, L. G., Fowler, P. & Chisari, F. V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161, 4520\u20134529 (1998).","journal-title":"J. Immunol."},{"key":"549_CR56","doi-asserted-by":"publisher","first-page":"8609","DOI":"10.1128\/JVI.76.17.8609-8620.2002","volume":"76","author":"K Kakimi","year":"2002","unstructured":"Kakimi, K., Isogawa, M., Chung, J., Sette, A. & Chisari, F. V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 76, 8609\u20138620 (2002).","journal-title":"J. Virol."},{"key":"549_CR57","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696\u2013699 (1995).","journal-title":"J. Hepatol."},{"key":"549_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","volume":"23","author":"P Fisicaro","year":"2017","unstructured":"Fisicaro, P. et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med. 23, 327\u2013336 (2017). This article suggests a central role for reactive oxygen species in T cell exhaustion during CHB, thus providing novel potential therapeutic targets.","journal-title":"Nat. Med."},{"key":"549_CR59","first-page":"a021469","volume":"5","author":"SF Wieland","year":"2015","unstructured":"Wieland, S. F. The chimpanzee model for hepatitis B virus infection. CSH Perspect. Med. 5, a021469 (2015).","journal-title":"CSH Perspect. Med."},{"key":"549_CR60","doi-asserted-by":"publisher","first-page":"14913","DOI":"10.1073\/pnas.0406282101","volume":"101","author":"MT Chen","year":"2004","unstructured":"Chen, M. T. et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl Acad. Sci. USA 101, 14913\u201314918 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR61","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1128\/JVI.79.5.3016-3027.2005","volume":"79","author":"M Chen","year":"2005","unstructured":"Chen, M. et al. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79, 3016\u20133027 (2005).","journal-title":"J. Virol."},{"key":"549_CR62","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.immuni.2016.04.008","volume":"44","author":"Y Tian","year":"2016","unstructured":"Tian, Y., Kuo, C., Akbari, O. & Ou, J. J. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 44, 1204\u20131214 (2016).","journal-title":"Immunity"},{"key":"549_CR63","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1172\/JCI68182","volume":"123","author":"J Publicover","year":"2013","unstructured":"Publicover, J. et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J. Clin. Invest. 123, 3728\u20133739 (2013).","journal-title":"J. Clin. Invest."},{"key":"549_CR64","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1073\/pnas.88.10.4186","volume":"88","author":"MR Brunetto","year":"1991","unstructured":"Brunetto, M. R. et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl Acad. Sci. USA 88, 4186\u20134190 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR65","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1172\/JCI92812","volume":"128","author":"L Rivino","year":"2018","unstructured":"Rivino, L. et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J. Clin. Invest. 128, 668\u2013681 (2018).","journal-title":"J. Clin. Invest."},{"key":"549_CR66","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","volume":"68","author":"A Schuch","year":"2019","unstructured":"Schuch, A. et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 68, 905\u2013915 (2019).","journal-title":"Gut"},{"key":"549_CR67","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200298","volume":"217","author":"V Fumagalli","year":"2020","unstructured":"Fumagalli, V. et al. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J. Exp. Med. 217, e20200298 (2020). This study shows that circulating HBsAg clearance does not improve HBV-specific CD8+ T cell responses.","journal-title":"J. Exp. Med."},{"key":"549_CR68","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","volume":"159","author":"NL Bert","year":"2020","unstructured":"Bert, N. L. et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology 159, 652\u2013664 (2020).","journal-title":"Gastroenterology"},{"key":"549_CR69","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26738","volume":"6","author":"Li","year":"2017","unstructured":"Li et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. eLife 6, e26738 (2017).","journal-title":"eLife"},{"key":"549_CR70","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","volume":"65","author":"T-Y Zhang","year":"2015","unstructured":"Zhang, T.-Y. et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 65, 658 (2015).","journal-title":"Gut"},{"key":"549_CR71","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/hep.23778","volume":"52","author":"Neumann","year":"2010","unstructured":"Neumann et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 52, 875\u2013885 (2010).","journal-title":"Hepatology"},{"key":"549_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/jhep.2002.31867","volume":"35","author":"E Galun","year":"2002","unstructured":"Galun, E. et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 35, 673\u2013679 (2002).","journal-title":"Hepatology"},{"key":"549_CR73","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1084\/jem.180.3.933","volume":"180","author":"A Bertoletti","year":"1994","unstructured":"Bertoletti, A. et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med. 180, 933\u2013943 (1994).","journal-title":"J. Exp. Med."},{"key":"549_CR74","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/369407a0","volume":"369","author":"A Bertoletti","year":"1994","unstructured":"Bertoletti, A. et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407\u2013410 (1994).","journal-title":"Nature"},{"key":"549_CR75","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1002\/1521-4141(200011)30:11<3067::AID-IMMU3067>3.0.CO;2-L","volume":"30","author":"MK Maini","year":"2000","unstructured":"Maini, M. K. et al. T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. Eur. J. Immunol. 30, 3067\u20133078 (2000).","journal-title":"Eur. J. Immunol."},{"key":"549_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/cmi.2014.79","volume":"12","author":"A Bertoletti","year":"2015","unstructured":"Bertoletti, A. & Kennedy, P. T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol. Immunol. 12, 258\u2013263 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"549_CR77","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","volume":"11","author":"P Fisicaro","year":"2020","unstructured":"Fisicaro, P. et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front. Immunol. 11, 849 (2020).","journal-title":"Front. Immunol."},{"key":"549_CR78","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton, A. R. et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J. Clin. Invest. 128, 4588\u20134603 (2018).","journal-title":"J. Clin. Invest."},{"key":"549_CR79","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573\u20134587 (2018). Together with Burton et al. (2018), this paper detects and characterizes dysfunctional HBsAg-specific B cell responses in patients with chronic HBV infection.","journal-title":"J. Clin. Invest."},{"key":"549_CR80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41426-018-0034-0","volume":"7","author":"C Tian","year":"2018","unstructured":"Tian, C. et al. Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans. Emerg. Microbes Infec 7, 16 (2018).","journal-title":"Emerg. Microbes Infec"},{"key":"549_CR81","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/cmi.2015.25","volume":"12","author":"X Xu","year":"2015","unstructured":"Xu, X. et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol. Immunol. 12, 309\u2013316 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"549_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","volume":"72","author":"NL Bert","year":"2019","unstructured":"Bert, N. L. et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J. Hepatol. 72, 34\u201344 (2019).","journal-title":"J. Hepatol."},{"key":"549_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jhep.2020.01.024","volume":"73","author":"T Vanwolleghem","year":"2020","unstructured":"Vanwolleghem, T. et al. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. J. Hepatol. 73, 52\u201361 (2020).","journal-title":"J. Hepatol."},{"key":"549_CR84","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1126\/science.3491425","volume":"234","author":"D Milich","year":"1986","unstructured":"Milich, D. & McLachlan, A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234, 1398\u20131401 (1986).","journal-title":"Science"},{"key":"549_CR85","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molimm.2012.10.032","volume":"55","author":"LG Guidotti","year":"2013","unstructured":"Guidotti, L. G. & Iannacone, M. Effector CD8 T cell trafficking within the liver. Mol. Immunol. 55, 94\u201399 (2013).","journal-title":"Mol. Immunol."},{"key":"549_CR86","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/cmi.2014.78","volume":"12","author":"M Iannacone","year":"2015","unstructured":"Iannacone, M. Hepatic effector CD8+ T-cell dynamics. Cell Mol. Immunol. 12, 269\u2013272 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"549_CR87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1189\/jlb.4MR0415-150R","volume":"99","author":"D Inverso","year":"2016","unstructured":"Inverso, D. & Iannacone, M. Spatiotemporal dynamics of effector CD8+ T cell responses within the liver. J. Leukoc. Biol. 99, 51\u201355 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"549_CR88","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2016.07.011","volume":"66","author":"AP Benechet","year":"2017","unstructured":"Benechet, A. P. & Iannacone, M. Determinants of hepatic effector CD8+ T cell dynamics. J. Hepatol. 66, 228\u2013233 (2017).","journal-title":"J. Hepatol."},{"key":"549_CR89","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","volume":"161","author":"LG Guidotti","year":"2015","unstructured":"Guidotti, L. G. et al. Immunosurveillance of the liver by intravascular effector CD8+ T cells. Cell 161, 486\u2013500 (2015). This manuscript reports that effector CD8+ T cells can recognize and kill antigen-expressing hepatocytes without extravasating by extending cytoplasmic protrusions through endothelial fenestration.","journal-title":"Cell"},{"key":"549_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/srep07341","volume":"4","author":"L Sironi","year":"2014","unstructured":"Sironi, L. et al. In vivo flow mapping in complex vessel networks by single image correlation. Sci. Rep. 4, 7341 (2014).","journal-title":"Sci. Rep."},{"key":"549_CR91","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.21378","volume":"44","author":"A Warren","year":"2006","unstructured":"Warren, A. et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44, 1182\u20131190 (2006).","journal-title":"Hepatology"},{"key":"549_CR92","doi-asserted-by":"publisher","first-page":"A80","DOI":"10.1016\/S0264-410X(02)00392-4","volume":"20","author":"LG Guidotti","year":"2002","unstructured":"Guidotti, L. G. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine 20, A80\u2013A82 (2002).","journal-title":"Vaccine"},{"key":"549_CR93","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2017.04.020","volume":"67","author":"J Fioravanti","year":"2017","unstructured":"Fioravanti, J. et al. Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. J. Hepatol. 67, 543\u2013548 (2017).","journal-title":"J. Hepatol."},{"key":"549_CR94","first-page":"a021477","volume":"5","author":"M Iannacone","year":"2015","unstructured":"Iannacone, M. & Guidotti, L. G. Mouse models of hepatitis B virus pathogenesis. CSH Perspect. Med. 5, a021477 (2015).","journal-title":"CSH Perspect. Med."},{"key":"549_CR95","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.191.7.1247","volume":"191","author":"LG Guidotti","year":"2000","unstructured":"Guidotti, L. G., McClary, H., Loudis, J. M. & Chisari, F. V. Nitric oxide inhibits hepatitis b virus replication in the livers of transgenic mice. J. Exp. Med. 191, 1247\u20131252 (2000).","journal-title":"J. Exp. Med."},{"key":"549_CR96","doi-asserted-by":"publisher","first-page":"9913","DOI":"10.1073\/pnas.0504273102","volume":"102","author":"SF Wieland","year":"2005","unstructured":"Wieland, S. F., Eustaquio, A., Whitten-Bauer, C., Boyd, B. & Chisari, F. V. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl Acad. Sci. USA 102, 9913\u20139917 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR97","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1128\/JVI.76.7.3570-3574.2002","volume":"76","author":"MD Robek","year":"2002","unstructured":"Robek, M. D., Wieland, S. F. & Chisari, F. V. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J. Virol. 76, 3570\u20133574 (2002).","journal-title":"J. Virol."},{"key":"549_CR98","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","volume":"150","author":"Y Xia","year":"2016","unstructured":"Xia, Y. et al. Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150, 194\u2013205 (2016).","journal-title":"Gastroenterology"},{"key":"549_CR99","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1172\/JCI116950","volume":"93","author":"TI Michalak","year":"1994","unstructured":"Michalak, T. I., Pasquinelli, C., Guilhot, S. & Chisari, F. V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Invest. 93, 230\u2013239 (1994).","journal-title":"J. Clin. Invest."},{"key":"549_CR100","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20162115","volume":"214","author":"LJ Pallett","year":"2017","unstructured":"Pallett, L. J. et al. IL-2high tissue-resident T cells in the human liver: sentinels for hepatotropic infection. J. Exp. Med. 214, 1567\u20131580 (2017). This paper characterizes tissue-resident memory T cells in the liver of patients chronically infected by HBV.","journal-title":"J. Exp. Med."},{"key":"549_CR101","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.4049\/jimmunol.152.7.3245","volume":"152","author":"K Ando","year":"1994","unstructured":"Ando, K. et al. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J. Immunol. 152, 3245\u20133253 (1994).","journal-title":"J. Immunol."},{"key":"549_CR102","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.4049\/jimmunol.158.12.5692","volume":"158","author":"Y Nakamoto","year":"1997","unstructured":"Nakamoto, Y., Guidotti, L. G., Pasquetto, V., Schreiber, R. D. & Chisari, F. V. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J. Immunol. 158, 5692\u20135697 (1997).","journal-title":"J. Immunol."},{"key":"549_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002061","volume":"7","author":"G Sitia","year":"2011","unstructured":"Sitia, G. et al. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog. 7, e1002061 (2011).","journal-title":"PLoS Pathog."},{"key":"549_CR104","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1189\/jlb.0306173","volume":"81","author":"Sitia","year":"2007","unstructured":"Sitia et al. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J. Leukoc. Biol. 81, 100\u2013107 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"549_CR105","doi-asserted-by":"publisher","first-page":"13717","DOI":"10.1073\/pnas.172521999","volume":"99","author":"G Sitia","year":"2002","unstructured":"Sitia, G. et al. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA 99, 13717\u201313722 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"549_CR106","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1172\/JCI200421087","volume":"113","author":"G Sitia","year":"2004","unstructured":"Sitia, G. et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 113, 1158\u20131167 (2004).","journal-title":"J. Clin. Invest."},{"key":"549_CR107","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","volume":"194","author":"K Kakimi","year":"2001","unstructured":"Kakimi, K. et al. Blocking chemokine responsive to \u03b3-2\/interferon (IFN)-\u03b3 inducible protein and monokine induced by IFN-\u03b3 activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755\u20131766 (2001).","journal-title":"J. Exp. Med."},{"key":"549_CR108","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","volume":"191","author":"MK Maini","year":"2000","unstructured":"Maini, M. K. et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191, 1269\u20131280 (2000).","journal-title":"J. Exp. Med."},{"key":"549_CR109","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1084\/jem.20011723","volume":"195","author":"S Reignat","year":"2002","unstructured":"Reignat, S. et al. Escaping high viral load exhaustion CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med. 195, 1089\u20131101 (2002).","journal-title":"J. Exp. Med."},{"key":"549_CR110","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","volume":"78","author":"GJM Webster","year":"2004","unstructured":"Webster, G. J. M. et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78, 5707\u20135719 (2004).","journal-title":"J. Virol."},{"key":"549_CR111","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215\u20134225 (2007).","journal-title":"J. Virol."},{"key":"549_CR112","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","volume":"68","author":"RC Hoogeveen","year":"2018","unstructured":"Hoogeveen, R. C. et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 68, 893\u2013904 (2018).","journal-title":"Gut"},{"key":"549_CR113","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.188.2.341","volume":"188","author":"Y Nakamoto","year":"1998","unstructured":"Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P. & Chisari, F. V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341\u2013350 (1998).","journal-title":"J. Exp. Med."},{"key":"549_CR114","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.immuni.2005.05.005","volume":"23","author":"M Isogawa","year":"2005","unstructured":"Isogawa, M., Furuichi, Y. & Chisari, F. V. Oscillating CD8+ T cell effector functions after antigen recognition in the liver. Immunity 23, 53\u201363 (2005).","journal-title":"Immunity"},{"key":"549_CR115","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01457-18","volume":"93","author":"A Khakpoor","year":"2018","unstructured":"Khakpoor, A. et al. Spatiotemporal differences in presentation of CD8 T cell epitopes during hepatitis B virus infection. J. Virol. 93, e01457-18 (2018).","journal-title":"J. Virol."},{"key":"549_CR116","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1158\/0008-5472.CAN-03-3817","volume":"64","author":"Y Nakamoto","year":"2004","unstructured":"Nakamoto, Y., Suda, T., Momoi, T. & Kaneko, S. Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res. 64, 3326\u20133333 (2004).","journal-title":"Cancer Res."},{"key":"549_CR117","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang, L. S. Y., Covert, E., Wilson, E. & Kottilil, S. Chronic hepatitis B infection: a review. JAMA 319, 1802\u20131813 (2018).","journal-title":"JAMA"},{"key":"549_CR118","first-page":"a021444","volume":"5","author":"M-A Buendia","year":"2015","unstructured":"Buendia, M.-A. & Neuveut, C. Hepatocellular carcinoma. CSH Perspect. Med. 5, a021444 (2015).","journal-title":"CSH Perspect. Med."},{"key":"549_CR119","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64, S84\u2013S101 (2016).","journal-title":"J. Hepatol."},{"key":"549_CR120","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1002\/hep.22962","volume":"49","author":"AMD Bisceglie","year":"2009","unstructured":"Bisceglie, A. M. D. Hepatitis B and hepatocellular carcinoma. Hepatology 49, S56\u2013S60 (2009).","journal-title":"Hepatology"},{"key":"549_CR121","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838\u2013851 (2008).","journal-title":"Lancet"},{"key":"549_CR122","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Invest."},{"key":"549_CR123","first-page":"98","volume":"1","author":"SL Friedman","year":"2004","unstructured":"Friedman, S. L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastr 1, 98\u2013105 (2004).","journal-title":"Nat. Clin. Pract. Gastr"},{"key":"549_CR124","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1317","volume":"11","author":"M Iannacone","year":"2005","unstructured":"Iannacone, M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1167\u20131169 (2005). This study establishes platelets as critical mediators of liver damage through their capacity to promote liver homing of effector CD8+ T cells.","journal-title":"Nat. Med."},{"key":"549_CR125","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas, A. et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metast Rev. 36, 289\u2013303 (2017).","journal-title":"Cancer Metast Rev."},{"key":"549_CR126","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V. & Sood, A. K. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33, 965\u2013983 (2018).","journal-title":"Cancer Cell"},{"key":"549_CR127","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1245\/s10434-016-5520-9","volume":"23","author":"P-C Lee","year":"2016","unstructured":"Lee, P.-C. et al. Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann. Surg. Oncol. 23, 874\u2013883 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"549_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23343-0","volume":"8","author":"IC Hwang","year":"2018","unstructured":"Hwang, I. C., Chang, J., Kim, K. & Park, S. M. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci. Rep. 8, 4968 (2018).","journal-title":"Sci. Rep."},{"key":"549_CR129","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2018.4154","volume":"4","author":"TG Simon","year":"2018","unstructured":"Simon, T. G. et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 4, 1683 (2018).","journal-title":"JAMA Oncol."},{"key":"549_CR130","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2018.8342","volume":"179","author":"T-Y Lee","year":"2019","unstructured":"Lee, T.-Y. et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern. Med. 179, 633\u2013640 (2019).","journal-title":"JAMA Intern. Med."},{"key":"549_CR131","doi-asserted-by":"publisher","first-page":"104585","DOI":"10.1016\/j.phrs.2019.104585","volume":"151","author":"S Wang","year":"2019","unstructured":"Wang, S. et al. Association of aspirin therapy with risk of hepatocellular carcinoma: a systematic review and dose\u2013response analysis of cohort studies with 2.5 million participants. Pharmacol. Res. 151, 104585 (2019).","journal-title":"Pharmacol. Res."},{"key":"549_CR132","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12876-020-1158-y","volume":"20","author":"Y-H Liao","year":"2020","unstructured":"Liao, Y.-H. et al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterol. 20, 6 (2020).","journal-title":"BMC Gastroenterol."},{"key":"549_CR133","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","volume":"31","author":"C Bosetti","year":"2020","unstructured":"Bosetti, C., Santucci, C., Gallus, S., Martinetti, M. & Vecchia, C. L. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann. Oncol. 31, 558\u2013568 (2020).","journal-title":"Ann. Oncol."},{"key":"549_CR134","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.3390\/cancers12113215","volume":"12","author":"T Hayashi","year":"2020","unstructured":"Hayashi, T. et al. Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma. Cancers 12, 3215 (2020).","journal-title":"Cancers"},{"key":"549_CR135","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1053\/j.gastro.2020.09.007","volume":"159","author":"LG Guidotti","year":"2020","unstructured":"Guidotti, L. G., Vecchia, C. L. & Colombo, M. Is it time to recommend low-dose aspirin treatment for the prevention of hepatocellular carcinoma? Gastroenterology 159, 1988\u20131990 (2020).","journal-title":"Gastroenterology"},{"key":"549_CR136","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.14364","volume":"40","author":"MG Martinez","year":"2020","unstructured":"Martinez, M. G., Villeret, F., Testoni, B. & Zoulim, F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int. 40, 27\u201334 (2020).","journal-title":"Liver Int."},{"key":"549_CR137","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1537-2995.1963.tb04673.x","volume":"3","author":"WD Hillis","year":"1963","unstructured":"Hillis, W. D. Viral hepatitis associated with sub-human primates. Transfusion 3, 445\u2013454 (1963).","journal-title":"Transfusion"},{"key":"549_CR138","first-page":"1","volume":"24","author":"E Walter","year":"1996","unstructured":"Walter, E., Keist, R., Nieder\u00f6st, B., Pult, I. & Blum, H. E. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24, 1\u20135 (1996).","journal-title":"Hepatology"},{"key":"549_CR139","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/hep.21896","volume":"46","author":"A Schulze","year":"2007","unstructured":"Schulze, A., Gripon, P. & Urban, S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46, 1759\u20131768 (2007).","journal-title":"Hepatology"},{"key":"549_CR140","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/hep.26125","volume":"57","author":"C Sureau","year":"2013","unstructured":"Sureau, C. & Salisse, J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A-determinant. Hepatology 57, 985\u2013994 (2013).","journal-title":"Hepatology"},{"key":"549_CR141","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep.1840210410","volume":"21","author":"T Roskams","year":"1995","unstructured":"Roskams, T. et al. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 21, 950\u2013958 (1995).","journal-title":"Hepatology"},{"key":"549_CR142","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).","journal-title":"eLife"},{"key":"549_CR143","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","volume":"70","author":"B D\u00f6ring","year":"2012","unstructured":"D\u00f6ring, B., L\u00fctteke, T., Geyer, J. & Petzinger, E. The SLC10 carrier family: transport functions and molecular structure. Curr. Top. Membr. 70, 105\u2013168 (2012).","journal-title":"Curr. Top. Membr."},{"key":"549_CR144","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/v9030056","volume":"9","author":"J Hu","year":"2017","unstructured":"Hu, J. & Liu, K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 9, 56 (2017).","journal-title":"Viruses"},{"key":"549_CR145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-virology-012420-024942","volume":"7","author":"S Seitz","year":"2020","unstructured":"Seitz, S., Habjani\u010d, J., Sch\u00fctz, A. K. & Bartenschlager, R. The hepatitis B virus envelope proteins: molecular gymnastics throughout the viral life cycle. Ann. Rev. Virol. 7, 1\u201326 (2020).","journal-title":"Ann. Rev. Virol."},{"key":"549_CR146","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/hep.1840050427","volume":"5","author":"E Wisse","year":"1985","unstructured":"Wisse, E., de Zanger, R. B., Charels, K., Van Der Smissen, P. & McCuskey, R. S. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse. Hepatology 5, 683\u2013692 (1985).","journal-title":"Hepatology"},{"key":"549_CR147","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba2351","volume":"5","author":"X Ficht","year":"2020","unstructured":"Ficht, X. & Iannacone, M. Immune surveillance of the liver by T cells. Sci. Immunol. 5, eaba2351 (2020).","journal-title":"Sci. Immunol."},{"key":"549_CR148","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/hep.28650","volume":"64","author":"Y Iwakiri","year":"2016","unstructured":"Iwakiri, Y. The lymphatic system: a new frontier in hepatology. Hepatology 64, 706\u2013707 (2016).","journal-title":"Hepatology"},{"key":"549_CR149","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","volume":"14","author":"CN Jenne","year":"2013","unstructured":"Jenne, C. N. & Kubes, P. Immune surveillance by the liver. Nat. Immunol. 14, 996\u20131006 (2013).","journal-title":"Nat. Immunol."},{"key":"549_CR150","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/cmi.2015.112","volume":"13","author":"AK Horst","year":"2016","unstructured":"Horst, A. K., Neumann, K., Diehl, L. & Tiegs, G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol. Immunol. 13, 277\u2013292 (2016).","journal-title":"Cell Mol. Immunol."},{"key":"549_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.53","volume":"5","author":"YC Wong","year":"2016","unstructured":"Wong, Y. C., McCaughan, G. W., Bowen, D. G. & Bertolino, P. The CD8 T-cell response during tolerance induction in liver transplantation. Clin. Transl Immunol. 5, e102 (2016).","journal-title":"Clin. Transl Immunol."},{"key":"549_CR152","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","volume":"151","author":"WS Mason","year":"2016","unstructured":"Mason, W. S. et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151, 986\u2013998.e4 (2016).","journal-title":"Gastroenterology"},{"key":"549_CR153","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu, T., Budzinska, M. A., Shackel, N. A. & Urban, S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses 9, 75 (2017).","journal-title":"Viruses"},{"key":"549_CR154","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/genes9070365","volume":"9","author":"MA Budzinska","year":"2018","unstructured":"Budzinska, M. A., Shackel, N. A., Urban, S. & Tu, T. Cellular genomic sites of hepatitis B virus DNA integration. Genes 9, 365 (2018).","journal-title":"Genes"},{"key":"549_CR155","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1128\/jvi.67.12.7032-7040.1993","volume":"67","author":"ZM Huang","year":"1993","unstructured":"Huang, Z. M. & Yen, T. S. Dysregulated surface gene expression from disrupted hepatitis B virus genomes. J. Virol. 67, 7032\u20137040 (1993).","journal-title":"J. Virol."},{"key":"549_CR156","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0016-5085(90)90028-Y","volume":"98","author":"HP Dienes","year":"1990","unstructured":"Dienes, H. P. et al. Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B. Gastroenterology 98, 1017\u20131023 (1990).","journal-title":"Gastroenterology"},{"key":"549_CR157","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/0092-8674(89)90770-8","volume":"59","author":"FV Chisari","year":"1989","unstructured":"Chisari, F. V. et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59, 1145\u20131156 (1989).","journal-title":"Cell"},{"key":"549_CR158","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/j.1440-1746.2008.05348.x","volume":"23","author":"I Su","year":"2008","unstructured":"Su, I., Wang, H., Wu, H. & Huang, W. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J. Gastroen Hepatol. 23, 1169\u20131174 (2008).","journal-title":"J. Gastroen Hepatol."},{"key":"549_CR159","first-page":"327","volume":"96","author":"S Hadziyannis","year":"1973","unstructured":"Hadziyannis, S., Gerber, M. A., Vissoulis, C. & Popper, H. Cytoplasmic hepatitis B antigen in \u201cground-glass\u201d hepatocytes of carriers. Arch. Pathol. 96, 327\u2013330 (1973).","journal-title":"Arch. Pathol."},{"key":"549_CR160","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jvh.12380","volume":"22","author":"T Tu","year":"2015","unstructured":"Tu, T. et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J. Viral Hepat. 22, 737\u2013753 (2015).","journal-title":"J. Viral Hepat."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00549-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:13:30Z","timestamp":1675296810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00549-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1038\/s41577-021-00549-4","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"1 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.I. participates in advisory boards\/consultancies for Gilead Sciences, Roche, Third Rock Ventures, Amgen, Asher Bio and Allovir. L.G.G is a member of the board of directors at Genenta Science and Epsilon Bio and participates in advisory boards\/consultancies for Gilead Sciences, Roche and Arbutus Biopharma. M.I. and L.G.G. are inventors on patents filed, owned and managed by San Raffaele Scientific Institute, Vita-Salute San Raffaele University and Telethon Foundation on technology related to work discussed in this manuscript (WO2020\/016434, WO2020\/016427, WO2020\/030781, WO2020\/234483, EU patent applications n. 19211249.8 and n. 20156716.1, and UK patent application n. 1907493.9).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}